TN2013000348A1 - Compounds and compositions as trk inhibitors - Google Patents

Compounds and compositions as trk inhibitors

Info

Publication number
TN2013000348A1
TN2013000348A1 TNP2013000348A TN2013000348A TN2013000348A1 TN 2013000348 A1 TN2013000348 A1 TN 2013000348A1 TN P2013000348 A TNP2013000348 A TN P2013000348A TN 2013000348 A TN2013000348 A TN 2013000348A TN 2013000348 A1 TN2013000348 A1 TN 2013000348A1
Authority
TN
Tunisia
Prior art keywords
compounds
compositions
trk inhibitors
trk
inhibitors
Prior art date
Application number
TNP2013000348A
Other languages
English (en)
Inventor
Valentina Molteni
Yi Fan
Jon Loren
Jeffrey M Smith
Brenton T Flatt
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45815979&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000348(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc filed Critical Irm Llc
Publication of TN2013000348A1 publication Critical patent/TN2013000348A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
TNP2013000348A 2011-02-25 2013-08-19 Compounds and compositions as trk inhibitors TN2013000348A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161446572P 2011-02-25 2011-02-25
PCT/US2012/026377 WO2012116217A1 (fr) 2011-02-25 2012-02-23 Composés et compositions en tant qu'inhibiteurs de trk

Publications (1)

Publication Number Publication Date
TN2013000348A1 true TN2013000348A1 (en) 2015-01-20

Family

ID=45815979

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000348A TN2013000348A1 (en) 2011-02-25 2013-08-19 Compounds and compositions as trk inhibitors

Country Status (27)

Country Link
US (1) US9102671B2 (fr)
EP (1) EP2678338B1 (fr)
JP (1) JP5959541B2 (fr)
KR (1) KR20140014184A (fr)
CN (1) CN103492384B (fr)
AP (1) AP2013007103A0 (fr)
AU (1) AU2012220572A1 (fr)
BR (1) BR112013021638A2 (fr)
CA (1) CA2828219A1 (fr)
CL (1) CL2013002430A1 (fr)
CO (1) CO6751270A2 (fr)
CR (1) CR20130410A (fr)
CU (1) CU20130115A7 (fr)
DO (1) DOP2013000192A (fr)
EA (1) EA201391230A1 (fr)
ES (1) ES2551592T3 (fr)
GE (1) GEP20156285B (fr)
GT (1) GT201300209A (fr)
IL (1) IL227987A0 (fr)
MA (1) MA34969B1 (fr)
MX (1) MX2013009767A (fr)
NI (1) NI201300073A (fr)
PE (1) PE20140378A1 (fr)
SG (1) SG192795A1 (fr)
TN (1) TN2013000348A1 (fr)
WO (1) WO2012116217A1 (fr)
ZA (1) ZA201306221B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2350075E (pt) 2008-09-22 2014-06-09 Array Biopharma Inc Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
MX365251B (es) 2010-05-20 2019-05-28 Array Biopharma Inc Compuestos macrocíclicos como inhibidores de trk cinasa.
CA2858958C (fr) * 2011-12-12 2016-10-04 Dr. Reddy's Laboratories Ltd. Pyrazolo[1,5-a]pyridines substituees en tant qu'inhibiteurs du recepteur kinase lie a la tropomyosine (trk)
US10407509B2 (en) 2013-07-30 2019-09-10 Blueprint Medicines Corporation NTRK2 fusions
SG11201605207PA (en) * 2013-12-26 2016-07-28 Ignyta Inc Pyrazolo[1,5-a]pyridine derivatives and methods of their use
PL3102555T3 (pl) * 2014-02-05 2021-12-20 VM Oncology LLC Kompozycje związków i ich zastosowania
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
CN113354649A (zh) 2014-11-16 2021-09-07 阵列生物制药公司 一种新的晶型
CN104529815B (zh) * 2014-12-04 2016-08-24 宁波欧迅化学新材料技术有限公司 合成2,4-二硝基苯氧胺的方法
US20180177792A1 (en) * 2015-05-29 2018-06-28 Ignyta, Inc. Compositions and methods for treating patients with rtk mutant cells
MA44936A1 (fr) 2015-06-01 2021-09-30 Loxo Oncology Inc Méthodes de diagnostic et de traitement du cancer
PL3322706T3 (pl) 2015-07-16 2021-07-19 Array Biopharma, Inc. Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret
CA3003153A1 (fr) 2015-10-26 2017-05-04 Loxo Oncology, Inc. Mutations ponctuelles dans le cancer resistant aux inhibiteurs de trk et methodes associees
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
KR20210010652A (ko) 2016-04-04 2021-01-27 록쏘 온콜로지, 인코포레이티드 소아암을 치료하는 방법
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
WO2018026798A1 (fr) * 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs de nmda spiro-lactame et leurs procédés d'utilisation
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
WO2018026779A1 (fr) 2016-08-01 2018-02-08 Aptinyx Inc. Modulateurs spiro-lactames des récepteurs nmda et leurs utilisations
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
CN108003161B (zh) * 2016-10-28 2020-10-09 正大天晴药业集团股份有限公司 神经营养因子酪氨酸激酶受体抑制剂
RU2764523C2 (ru) 2016-10-28 2022-01-18 Чиа Тай Тянцин Фармасьютикал Груп Ко., Лтд. Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора
WO2018136661A1 (fr) 2017-01-18 2018-07-26 Andrews Steven W Composés de pyrazolo[1,5-a]pyrazine substitués utilisés en tant qu'inhibiteurs de la kinase ret
WO2018136663A1 (fr) 2017-01-18 2018-07-26 Array Biopharma, Inc. Inhibiteurs de ret
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3071032A1 (fr) 2017-08-23 2019-02-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Macrocycle contenant de l'aminopyrazole et de la pyrimidine, composition pharmaceutique et utilisation de celui-ci
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
KR102653681B1 (ko) 2018-07-31 2024-04-03 록쏘 온콜로지, 인코포레이티드 (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
CN111171019A (zh) * 2018-11-13 2020-05-19 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
EP3898615A1 (fr) 2018-12-19 2021-10-27 Array Biopharma, Inc. Dérivés de 7-((3,5-diméthoxyphényl)amino)quinoxaline servant d'inhibiteurs de fgfr pour le traitement du cancer
CN113490666A (zh) 2018-12-19 2021-10-08 奥瑞生物药品公司 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物
WO2020187291A1 (fr) 2019-03-19 2020-09-24 华中师范大学 Composé de pyrazolopyrimidine, composition pharmaceutique et utilisation associée
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
CN110804059B (zh) * 2019-09-30 2024-03-12 郑州泰基鸿诺医药股份有限公司 氨基甲酸酯类化合物、药物组合物及其应用
CN110643672A (zh) * 2019-10-15 2020-01-03 西安交通大学 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
CN112779518B (zh) * 2020-12-17 2022-07-22 东北师范大学 一种高发光强度的薄膜、制备方法及其用途
CN112645955B (zh) * 2020-12-24 2022-11-04 四川国康药业有限公司 一种[1,2,4]***并[4,3-b]哒嗪类化合物及其制备方法和用途
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
US5451700A (en) 1991-06-11 1995-09-19 Ciba-Geigy Corporation Amidino compounds, their manufacture and methods of treatment
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
US5605923A (en) 1992-04-02 1997-02-25 Smithkline Beecham Corporation Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
MX9301943A (es) 1992-04-02 1994-08-31 Smithkline Beecham Corp Compuestos.
WO1993019750A1 (fr) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Composes efficaces dans le traitement de maladies allergiques ou inflammatoires
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
GB9414208D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723589D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
PE20000270A1 (es) 1998-02-14 2000-05-20 Glaxo Group Ltd Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
AU750462B2 (en) 1998-06-23 2002-07-18 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
GB9813540D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813565D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
BR9815931A (pt) 1998-06-30 2001-02-20 Dow Chemical Co Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida
CA2347512C (fr) 1998-10-16 2005-12-06 Pfizer Inc. Derives d'adenine
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
SK287231B6 (sk) 1999-08-21 2010-04-07 Nycomed Gmbh Liečivo zahŕňajúce PDE inhibítor a agonistu beta2 adrenoreceptora
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
KR20020093083A (ko) 2000-04-27 2002-12-12 베링거 잉겔하임 파르마 카게 신규한 완효성 베타모사체, 이의 제조방법 및 약제로서의이의 용도
TWI227240B (en) 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
GB0015727D0 (en) 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
ES2213703T5 (es) 2000-06-27 2011-11-02 Laboratorios S.A.L.V.A.T., S.A. Carbamatos derivados de arilalquilaminas.
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
JP2002114788A (ja) * 2000-08-03 2002-04-16 Banyu Pharmaceut Co Ltd カルバペネム誘導体の製造方法及び合成中間体
AR032361A1 (es) 2000-08-05 2003-11-05 Glaxo Group Ltd Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
WO2002051841A1 (fr) 2000-12-22 2002-07-04 Almirall Prodesfarma Ag Derives de carbamate quinuclidine et leur utilisation comme antagonistes m3
AU2002238471B2 (en) 2000-12-28 2007-06-28 Almirall, S.A. Quinuclidine derivatives and their use as M3 antagonists
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
DE60220887T2 (de) 2001-03-08 2008-02-28 Glaxo Group Ltd., Greenford Agonisten von beta-adrenorezeptoren
EP1241176A1 (fr) 2001-03-16 2002-09-18 Pfizer Products Inc. Dérivés de purine pour le traitement de l'ischémie
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
WO2002088167A1 (fr) 2001-04-30 2002-11-07 Glaxo Group Limited Derives anti-inflammatoires d'androstane 17.beta.-carbothioate ester avec un groupe cyclique en position 17.alpha
PL366899A1 (en) 2001-05-25 2005-02-07 Pfizer Inc. An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
JP4405258B2 (ja) 2001-06-21 2010-01-27 ヴェレニウム コーポレイション ニトリラーゼ
BRPI0212455B8 (pt) 2001-09-14 2021-05-25 Glaxo Group Ltd composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
KR20050030169A (ko) 2001-10-17 2005-03-29 유씨비 소시에떼아노님 퀴누클리딘 유도체, 이의 제조 방법 및 ｍ2 및/또는 ｍ3무스카린 수용체 억제제로서의 이의 용도
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
NZ532816A (en) 2001-11-09 2005-11-25 Cv Therapeutics Inc A2B adenosine receptor antagonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (fr) 2001-11-13 2003-05-22 Theravance, Inc. Agonistes de recepteur d'aryl aniline beta-2 adrenergique
WO2003048181A1 (fr) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha.-esters cycliques de 16-methylpregnan-3,20-dione en tant qu'agents anti-inflammatoires
BR0215348A (pt) 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
AU2003202044A1 (en) 2002-01-15 2003-09-09 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (fr) 2002-01-21 2003-07-31 Glaxo Group Limited Nouveaux composes
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US6903215B2 (en) 2002-03-26 2005-06-07 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CA2477764A1 (fr) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Mimetiques du glucocorticoide, procedes de fabrication de ces mimetiques, compositions pharmaceutiques et leurs utilisations
AU2003234716A1 (en) 2002-04-10 2003-10-27 Joel M. Linden Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
ATE496620T1 (de) 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
DE60318193T2 (de) 2002-04-25 2008-12-04 Glaxo Group Ltd., Greenford Phenethanolaminderivate
AU2003239880A1 (en) 2002-05-28 2003-12-12 Theravance, Inc. ALKOXY ARYL Beta2 ADRENERGIC RECEPTOR AGONISTS
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
JP2006502104A (ja) 2002-06-25 2006-01-19 メルク フロスト カナダ アンド カンパニー ８−（ビアリール）キノリンｐｄｅ４阻害剤
JP2005538972A (ja) 2002-07-02 2005-12-22 メルク フロスト カナダ アンド カンパニー ジアリール置換エタンピリドンｐｄｅ４阻害剤
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
WO2004005229A1 (fr) 2002-07-08 2004-01-15 Pfizer Products Inc. Modulateurs du recepteur glucocorticoide
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
PL373146A1 (en) 2002-08-10 2005-08-22 Altana Pharma Ag Pyridazinone-derivatives as pde4 inhibitors
WO2004018450A1 (fr) 2002-08-10 2004-03-04 Altana Pharma Ag Derives de n-oxyde de piperidine
WO2004017974A1 (fr) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones et phthalazones en tant qu'inhibiteurs de pde4
RS20050117A (en) 2002-08-17 2007-06-04 Altana Pharma Ag., Novel benzonaphthyridines
WO2004018431A2 (fr) 2002-08-17 2004-03-04 Altana Pharma Ag Nouvelles phenanthridines
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1534675B1 (fr) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo(3.1.0)hexanes 3,6-disubstitues contenant fluoro et sulfonylamino, utilises comme antagonistes des recepteurs de muscarine
CN1678306A (zh) 2002-08-29 2005-10-05 贝林格尔·英格海姆药物公司 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
DE60310576T2 (de) 2002-08-29 2007-10-31 Altana Pharma Ag 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 2002-08-29 2007-02-15 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
WO2004026248A2 (fr) 2002-09-20 2004-04-01 Merck & Co., Inc. Derives d'octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide en tant que modulateurs selectifs de recepteur glucocorticoide
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
AU2003269316A1 (en) 2002-10-11 2004-05-04 Pfizer Inc. Indole derivatives as beta-2 agonists
EP1440966A1 (fr) 2003-01-10 2004-07-28 Pfizer Limited Dérivés d'indole utilisables pour traiter des maladies
DE60315492T2 (de) 2002-10-22 2008-04-24 Glaxo Group Ltd., Greenford Medizinisch verwendbare arylethanolamin verbindungen
KR20050065624A (ko) 2002-10-23 2005-06-29 그렌마크 파머수티칼스 엘티디. 염증성 및 알레르기 질환의 치료에 유용한 신규한트리사이클릭 화합물, 이의 제조 방법 및 이를 함유하는약제 조성물
US7442839B2 (en) 2002-10-28 2008-10-28 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
PL378245A1 (pl) 2003-01-09 2006-03-20 Astellas Pharma Inc. Pochodne pirolopirydazyny
US7732432B2 (en) 2003-01-21 2010-06-08 Merck Sharp & Dohme Corp. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
EP1460064A1 (fr) 2003-03-14 2004-09-22 Pfizer Limited Derivés de Indole-2-carboxamide comme beta-2 agonistes
EP1615881A2 (fr) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyle et composes apparentes ayant les activites agoniste du recepteur beta2 adrenergique et antagoniste de recepteur de muscarinic
EP1613315B1 (fr) 2003-04-04 2009-01-21 Novartis AG Derives de quinoline-2-one permettant de traiter des maladies des voies respiratoires
AR044134A1 (es) 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
EP1477167A1 (fr) 2003-05-15 2004-11-17 Pfizer Limited Dérivés de [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl come agonistes de beta2
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
EP1626970B1 (fr) 2003-05-28 2009-07-08 Theravance, Inc. Composes d'azabicycloalcane utilises en tant qu'antagonistes des recepteurs muscariniques
BRPI0410660A (pt) 2003-06-04 2006-06-20 Pfizer derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
JP2006527207A (ja) 2003-06-11 2006-11-30 メルク フロスト カナダ リミテツド ７−（１，３−チアゾール−２−イル）チオ−クマリン誘導体およびそれのロイコトリエン生合成阻害薬としての使用
WO2004111044A1 (fr) 2003-06-17 2004-12-23 Glenmark Pharmaceuticals Ltd. Composes tricycliques efficaces dans le traitement des affections inflammatoires et allergiques : leur procede de preparation
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ITMI20031451A1 (it) 2003-07-16 2005-01-17 Zambon Spa Derivati diidro-ftalazinici inibitori della fosfodiesterasi 4
EP1658271A1 (fr) 2003-07-31 2006-05-24 ALTANA Pharma AG Nouvelles 6-phenylphenanthridines
EP1658270A1 (fr) 2003-07-31 2006-05-24 ALTANA Pharma AG Nouvelles 6-phenylphenanthridines
US20060234984A1 (en) * 2003-08-15 2006-10-19 Coleman Paul J Mitotic kinesin inhibitors
GB0322722D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
GB0322726D0 (en) 2003-09-27 2003-10-29 Glaxo Group Ltd Compounds
WO2005033121A2 (fr) 2003-10-03 2005-04-14 King Pharmaceuticals Research & Development, Inc. Synthese de 2-aralkyloxyadenosines, 2-alkoxyadenosines, et leurs analogues
GB0323701D0 (en) 2003-10-09 2003-11-12 Glaxo Group Ltd Formulations
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0329182D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Chemical compounds
US7648625B2 (en) 2003-12-19 2010-01-19 Shell Oil Company Systems, methods, and catalysts for producing a crude product
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
DE102004001413A1 (de) 2004-01-09 2005-08-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Hydroxymethyl-4-Hydroxy-Phenyl-Derivate zur Behandlung von chronisch obstruktiver Lungenerkrankung
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
AU2005214153B2 (en) 2004-01-22 2008-09-18 Pfizer Inc. Sulfonamide derivatives for the treatment of diseases
CA2553293C (fr) 2004-01-22 2010-12-14 Pfizer Inc. Derives de sulfamides pour traitements medicaux
DE102004003428A1 (de) 2004-01-23 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Beta-2-Agonisten, und deren Verwendung als Arzneimittel
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
WO2005080375A1 (fr) 2004-02-13 2005-09-01 Theravance, Inc. Cristalline d'un compose biphenyle
DE502005010170D1 (de) 2004-02-14 2010-10-14 Boehringer Ingelheim Pharma Neue langwirksame beta-2-agonisten, und deren verwendung als arzneimittel
BRPI0508481A (pt) 2004-03-10 2007-07-31 Altana Pharma Ag hidróxi-6-fenilenantridinas amido-substituìdas e seu uso como inibidores de pde4
US20080161339A1 (en) 2004-03-10 2008-07-03 Altana Pharma Ag Novel Thio-Containing Hydroxy-6-Phenylphenanthridines and their Use as Pde4 Inhibitors
EP1574501A1 (fr) 2004-03-11 2005-09-14 Pfizer Limited Dérivés de quinoléinone, compositions pharmaceutiques les contenant et leur usage
EP1726584A4 (fr) 2004-03-15 2009-05-13 Kyowa Hakko Kirin Co Ltd Derive de 2-aminoquinazoline
EP1727789A2 (fr) 2004-03-17 2006-12-06 Pfizer Limited Dérivés béta-2 agonistes de la phényléthanolamine
US7244728B2 (en) 2004-03-17 2007-07-17 Boehringer Ingelheim International Gmbh Long acting betamimetics for the treatment of respiratory diseases
EP1577292A1 (fr) 2004-03-17 2005-09-21 Pfizer Limited Dérivées de phenylaminoethanol comme agonistes des recepteurs beta2
WO2005090345A1 (fr) 2004-03-17 2005-09-29 Altana Pharma Ag Nouveaux derives de 6-phenyl-benzonaphtyridines a substitution n-(alcoxyalkyl) carbamoyle et leur utilisation comme inhibiteurs de pde3/4
US20050215542A1 (en) 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
WO2005092860A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes servant au traitement de maladies
WO2005092887A1 (fr) 2004-03-23 2005-10-06 Pfizer Limited Composes pour le traitement de maladies
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
BRPI0509382A (pt) 2004-04-02 2007-09-18 Glaxo Group Ltd processo para a preparação de um sal monocloridrato de composto, monocloridrato cristalino, processo para obter monocloridrato cristalino, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, uso de monocloridrato cristalino, formulação farmacêutica, e, combinação
DE102004019539A1 (de) 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von Atemwegserkrankungen
US20050239778A1 (en) 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US7307076B2 (en) 2004-05-13 2007-12-11 Boehringer Ingelheim International Gmbh Beta agonists for the treatment of respiratory diseases
US20050256115A1 (en) 2004-05-14 2005-11-17 Boehringer Ingelheim International Gmbh Aerosol formulation for the inhalation of beta-agonists
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
WO2005121065A2 (fr) 2004-06-03 2005-12-22 Theravance, Inc. Agonistes des recepteurs $g(b)2-adrenergiques diaminiques
WO2006014704A1 (fr) 2004-07-21 2006-02-09 Theravance, Inc. AGONISTES DES RÉCEPTEURS β2-ADRÉNERGIQUES DÉRIVÉS D'ÉTHERS DE DIARYLE
GB0416397D0 (en) 2004-07-22 2004-08-25 Glaxo Group Ltd Pharmaceutical formulations
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
US7838597B2 (en) 2004-08-20 2010-11-23 Sekisui Specialty Chemicals America, Llc Fluid loss concentrate for hydraulic cement
JP2008512470A (ja) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
MX2007014053A (es) * 2005-05-13 2008-02-05 Lilly Co Eli N-arilpirrolidinas substituidas como moduladores selectivos de receptor de androgeno.
CA2703106C (fr) * 2007-10-24 2015-12-01 Astellas Pharma Inc. Derives d'azolecarboxamide comme inhibiteurs de trka
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases
WO2010021878A1 (fr) * 2008-08-19 2010-02-25 Janssen Pharmaceutica Nv Antagonistes des récepteurs au froid activés par le menthol
SG10201914059WA (en) * 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
TW201022233A (en) * 2008-11-04 2010-06-16 Organon Nv (Pyrrolidin-2-yl)phenyl derivatives
WO2010117787A2 (fr) * 2009-03-30 2010-10-14 The Brigham And Women's Hospital, Inc. Inhibition de l'enzyme ephb3 kinase
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors

Also Published As

Publication number Publication date
CN103492384B (zh) 2016-05-11
CL2013002430A1 (es) 2013-11-29
JP2014506599A (ja) 2014-03-17
ES2551592T3 (es) 2015-11-20
GT201300209A (es) 2015-06-02
CO6751270A2 (es) 2013-09-16
US20130331397A1 (en) 2013-12-12
CU20130115A7 (es) 2013-12-27
ZA201306221B (en) 2014-04-30
AP2013007103A0 (en) 2013-09-30
GEP20156285B (en) 2015-05-11
EP2678338A1 (fr) 2014-01-01
MX2013009767A (es) 2013-10-01
EA201391230A1 (ru) 2014-01-30
CN103492384A (zh) 2014-01-01
PE20140378A1 (es) 2014-03-28
SG192795A1 (en) 2013-09-30
AU2012220572A1 (en) 2013-08-29
CA2828219A1 (fr) 2012-08-30
WO2012116217A1 (fr) 2012-08-30
CR20130410A (es) 2013-10-17
DOP2013000192A (es) 2014-01-31
KR20140014184A (ko) 2014-02-05
EP2678338B1 (fr) 2015-09-09
BR112013021638A2 (pt) 2016-08-02
IL227987A0 (en) 2013-09-30
US9102671B2 (en) 2015-08-11
NI201300073A (es) 2013-12-17
JP5959541B2 (ja) 2016-08-02
MA34969B1 (fr) 2014-03-01

Similar Documents

Publication Publication Date Title
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
JOP20120246B1 (ar) مركبات و تركيبات كمثبطات كيناز c-Kit
MX339937B (es) Compuestos y composiciones como inhibidores de la quinasa c-kit.
UY33597A (es) Compuestos y composiciones como inhibidores de la trk
MX2014002486A (es) Compuestos y composiciones como inhibidores de cinasa pdgfr.
JO3002B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
IN2014KN02601A (fr)
MY165728A (en) Selective glycosidase inhibitors and uses thereof
MA32393B1 (fr) Composés et compositions servant d'inhibiteurs de kinases
MX364602B (es) Inhibidores selectivos de glicosidasa y usos de los mismos.
IN2015DN01151A (fr)
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
PH12014501979B1 (en) Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors